167 related articles for article (PubMed ID: 10682679)
1. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
Saunders MP; Patterson AV; Chinje EC; Harris AL; Stratford IJ
Br J Cancer; 2000 Feb; 82(3):651-6. PubMed ID: 10682679
[TBL] [Abstract][Full Text] [Related]
2. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
Elwell JH; Siim BG; Evans JW; Brown JM
Biochem Pharmacol; 1997 Jul; 54(2):249-57. PubMed ID: 9271329
[TBL] [Abstract][Full Text] [Related]
3. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
Patterson AV; Saunders MP; Chinje EC; Talbot DC; Harris AL; Strafford IJ
Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
[TBL] [Abstract][Full Text] [Related]
5. Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.
Guise CP; Abbattista MR; Anderson RF; Li D; Taghipouran R; Tsai A; Lee SJ; Smaill JB; Denny WA; Hay MP; Wilson WR; Hicks KO; Patterson AV
Molecules; 2020 Oct; 25(21):. PubMed ID: 33105798
[TBL] [Abstract][Full Text] [Related]
6. Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
Chinje EC; Patterson AV; Saunders MP; Lockyer SD; Harris AL; Stratford IJ
Br J Cancer; 1999 Dec; 81(7):1127-33. PubMed ID: 10584872
[TBL] [Abstract][Full Text] [Related]
7. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
Patterson AV; Barham HM; Chinje EC; Adams GE; Harris AL; Stratford IJ
Br J Cancer; 1995 Nov; 72(5):1144-50. PubMed ID: 7577460
[TBL] [Abstract][Full Text] [Related]
8. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.
Chinje EC; Cowen RL; Feng J; Sharma SP; Wind NS; Harris AL; Stratford IJ
Mol Pharmacol; 2003 Jun; 63(6):1248-55. PubMed ID: 12761334
[TBL] [Abstract][Full Text] [Related]
9. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of tirapazamine by multiple reductases in the nucleus.
Delahoussaye YM; Evans JW; Brown JM
Biochem Pharmacol; 2001 Nov; 62(9):1201-9. PubMed ID: 11705453
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure.
Cowen RL; Williams KJ; Chinje EC; Jaffar M; Sheppard FC; Telfer BA; Wind NS; Stratford IJ
Cancer Res; 2004 Feb; 64(4):1396-402. PubMed ID: 14973055
[TBL] [Abstract][Full Text] [Related]
12. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
13. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors.
Hicks KO; Siim BG; Pruijn FB; Wilson WR
Radiat Res; 2004 Jun; 161(6):656-66. PubMed ID: 15161354
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
Hicks KO; Siim BG; Jaiswal JK; Pruijn FB; Fraser AM; Patel R; Hogg A; Liyanage HD; Dorie MJ; Brown JM; Denny WA; Hay MP; Wilson WR
Clin Cancer Res; 2010 Oct; 16(20):4946-57. PubMed ID: 20732963
[TBL] [Abstract][Full Text] [Related]
15. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents.
Garner AP; Paine MJ; Rodriguez-Crespo I; Chinje EC; Ortiz De Montellano P; Stratford IJ; Tew DG; Wolf CR
Cancer Res; 1999 Apr; 59(8):1929-34. PubMed ID: 10213502
[TBL] [Abstract][Full Text] [Related]
17. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer.
Wouters BG; Wang LH; Brown JM
Ann Oncol; 1999; 10 Suppl 5():S29-33. PubMed ID: 10582136
[TBL] [Abstract][Full Text] [Related]
18. Large-scale analysis of genes that alter sensitivity to the anticancer drug tirapazamine in Saccharomyces cerevisiae.
Hellauer K; Lesage G; Sdicu AM; Turcotte B
Mol Pharmacol; 2005 Nov; 68(5):1365-75. PubMed ID: 16061773
[TBL] [Abstract][Full Text] [Related]
19. 3-amino-1,2,4-benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Fuchs T; Chowdhury G; Barnes CL; Gates KS
J Org Chem; 2001 Jan; 66(1):107-14. PubMed ID: 11429885
[TBL] [Abstract][Full Text] [Related]
20. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.
Delahoussaye YM; Hay MP; Pruijn FB; Denny WA; Brown JM
Biochem Pharmacol; 2003 Jun; 65(11):1807-15. PubMed ID: 12781332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]